vs
Dutch Bros Inc.（BROS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Dutch Bros Inc.的1.7倍（$772.1M vs $443.6M），Revvity净利率更高（12.7% vs 4.8%，领先7.9%），Dutch Bros Inc.同比增速更快（29.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $8.5M），过去两年Dutch Bros Inc.的营收复合增速更高（27.0% vs 9.0%）
Dutch Bros Inc.是美国上市得来速咖啡连锁品牌，1992年由戴恩·博尔斯马与特拉维斯·博尔斯马创立，原总部位于俄勒冈州格兰茨帕斯，2025年迁至亚利桑那州坦佩。品牌拥有直营及加盟门店，主力布局美国西部市场，目前扩张范围最东已覆盖佛罗里达州奥兰多。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BROS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$443.6M
营收增速更快
BROS
高出23.6%
5.9%
净利率更高
RVTY
高出7.9%
4.8%
自由现金流更多
RVTY
多$153.3M
$8.5M
两年增速更快
BROS
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $443.6M | $772.1M |
| 净利润 | $21.4M | $98.4M |
| 毛利率 | 24.1% | — |
| 营业利润率 | 7.7% | 14.5% |
| 净利率 | 4.8% | 12.7% |
| 营收同比 | 29.4% | 5.9% |
| 净利润同比 | 491.6% | 3.9% |
| 每股收益（稀释后） | $0.17 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BROSRVTY
| Q4 25 | $443.6M | $772.1M | ||
| Q3 25 | $423.6M | $698.9M | ||
| Q2 25 | $415.8M | $720.3M | ||
| Q1 25 | $355.2M | $664.8M | ||
| Q4 24 | $342.8M | $729.4M | ||
| Q3 24 | $338.2M | $684.0M | ||
| Q2 24 | $324.9M | $691.7M | ||
| Q1 24 | $275.1M | $649.9M |
净利润BROSRVTY
| Q4 25 | $21.4M | $98.4M | ||
| Q3 25 | $17.5M | $46.7M | ||
| Q2 25 | $25.6M | $53.9M | ||
| Q1 25 | $15.4M | $42.2M | ||
| Q4 24 | $3.6M | $94.6M | ||
| Q3 24 | $12.6M | $94.4M | ||
| Q2 24 | $11.9M | $55.4M | ||
| Q1 24 | $7.1M | $26.0M |
毛利率BROSRVTY
| Q4 25 | 24.1% | — | ||
| Q3 25 | 25.2% | 53.6% | ||
| Q2 25 | 28.9% | 54.5% | ||
| Q1 25 | 25.3% | 56.5% | ||
| Q4 24 | 25.7% | — | ||
| Q3 24 | 26.6% | 56.3% | ||
| Q2 24 | 27.8% | 55.7% | ||
| Q1 24 | 26.1% | 54.6% |
营业利润率BROSRVTY
| Q4 25 | 7.7% | 14.5% | ||
| Q3 25 | 9.8% | 11.7% | ||
| Q2 25 | 13.1% | 12.6% | ||
| Q1 25 | 8.7% | 10.9% | ||
| Q4 24 | 4.6% | 16.3% | ||
| Q3 24 | 9.6% | 14.3% | ||
| Q2 24 | 9.9% | 12.4% | ||
| Q1 24 | 9.3% | 6.8% |
净利率BROSRVTY
| Q4 25 | 4.8% | 12.7% | ||
| Q3 25 | 4.1% | 6.7% | ||
| Q2 25 | 6.2% | 7.5% | ||
| Q1 25 | 4.3% | 6.4% | ||
| Q4 24 | 1.1% | 13.0% | ||
| Q3 24 | 3.7% | 13.8% | ||
| Q2 24 | 3.7% | 8.0% | ||
| Q1 24 | 2.6% | 4.0% |
每股收益（稀释后）BROSRVTY
| Q4 25 | $0.17 | $0.86 | ||
| Q3 25 | $0.14 | $0.40 | ||
| Q2 25 | $0.20 | $0.46 | ||
| Q1 25 | $0.13 | $0.35 | ||
| Q4 24 | $0.03 | $0.77 | ||
| Q3 24 | $0.11 | $0.77 | ||
| Q2 24 | $0.12 | $0.45 | ||
| Q1 24 | $0.08 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $269.4M | $919.9M |
| 总债务越低越好 | $202.5M | — |
| 股东权益账面价值 | $680.8M | $7.3B |
| 总资产 | $3.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资BROSRVTY
| Q4 25 | $269.4M | $919.9M | ||
| Q3 25 | $267.2M | $931.4M | ||
| Q2 25 | $254.4M | $991.8M | ||
| Q1 25 | $316.4M | $1.1B | ||
| Q4 24 | $293.4M | $1.2B | ||
| Q3 24 | $281.1M | $1.2B | ||
| Q2 24 | $260.9M | $2.0B | ||
| Q1 24 | $262.7M | $1.7B |
总债务BROSRVTY
| Q4 25 | $202.5M | — | ||
| Q3 25 | $202.3M | — | ||
| Q2 25 | $203.3M | — | ||
| Q1 25 | $284.2M | — | ||
| Q4 24 | $238.0M | — | ||
| Q3 24 | $241.2M | — | ||
| Q2 24 | $244.3M | — | ||
| Q1 24 | $247.5M | — |
股东权益BROSRVTY
| Q4 25 | $680.8M | $7.3B | ||
| Q3 25 | $656.6M | $7.4B | ||
| Q2 25 | $636.2M | $7.6B | ||
| Q1 25 | $599.1M | $7.6B | ||
| Q4 24 | $537.4M | $7.7B | ||
| Q3 24 | $523.1M | $7.9B | ||
| Q2 24 | $509.1M | $7.9B | ||
| Q1 24 | $417.1M | $7.8B |
总资产BROSRVTY
| Q4 25 | $3.0B | $12.2B | ||
| Q3 25 | $2.9B | $12.1B | ||
| Q2 25 | $2.8B | $12.4B | ||
| Q1 25 | $2.8B | $12.4B | ||
| Q4 24 | $2.5B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
负债/权益比BROSRVTY
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.46× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $79.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $8.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.9% | 21.0% |
| 资本支出强度资本支出/营收 | 16.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.73× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $54.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BROSRVTY
| Q4 25 | $79.6M | $182.0M | ||
| Q3 25 | $89.1M | $138.5M | ||
| Q2 25 | $89.9M | $134.3M | ||
| Q1 25 | $36.9M | $128.2M | ||
| Q4 24 | $62.2M | $174.2M | ||
| Q3 24 | $83.5M | $147.9M | ||
| Q2 24 | $59.5M | $158.6M | ||
| Q1 24 | $41.2M | $147.6M |
自由现金流BROSRVTY
| Q4 25 | $8.5M | $161.8M | ||
| Q3 25 | $18.9M | $120.0M | ||
| Q2 25 | $35.7M | $115.5M | ||
| Q1 25 | $-8.7M | $112.2M | ||
| Q4 24 | $19.5M | $149.8M | ||
| Q3 24 | $26.4M | $125.6M | ||
| Q2 24 | $-4.9M | $136.6M | ||
| Q1 24 | $-16.3M | $129.7M |
自由现金流率BROSRVTY
| Q4 25 | 1.9% | 21.0% | ||
| Q3 25 | 4.5% | 17.2% | ||
| Q2 25 | 8.6% | 16.0% | ||
| Q1 25 | -2.4% | 16.9% | ||
| Q4 24 | 5.7% | 20.5% | ||
| Q3 24 | 7.8% | 18.4% | ||
| Q2 24 | -1.5% | 19.7% | ||
| Q1 24 | -5.9% | 20.0% |
资本支出强度BROSRVTY
| Q4 25 | 16.0% | 2.6% | ||
| Q3 25 | 16.6% | 2.6% | ||
| Q2 25 | 13.0% | 2.6% | ||
| Q1 25 | 12.8% | 2.4% | ||
| Q4 24 | 12.5% | 3.4% | ||
| Q3 24 | 16.9% | 3.3% | ||
| Q2 24 | 19.8% | 3.2% | ||
| Q1 24 | 20.9% | 2.7% |
现金转化率BROSRVTY
| Q4 25 | 3.73× | 1.85× | ||
| Q3 25 | 5.09× | 2.97× | ||
| Q2 25 | 3.51× | 2.49× | ||
| Q1 25 | 2.40× | 3.03× | ||
| Q4 24 | 17.23× | 1.84× | ||
| Q3 24 | 6.60× | 1.57× | ||
| Q2 24 | 4.99× | 2.87× | ||
| Q1 24 | 5.83× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BROS
| Company Operated Shops | $409.6M | 92% |
| Franchise Fees | $32.3M | 7% |
| Other | $1.8M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
